The regulatory future for peptides — what's coming and what it means

The starting point is the FDA approval framework, which works as follows: a pharmaceutical company develops a drug, demonstrates safety and efficacy in clinical trials, and receives FDA approval for a specific drug at a specific indication manufactured under specific conditions. That drug then occupies a defined regulatory space — it is what it is, it does what it's approved to do, and it's manufactured to standards that the FDA has verified. The compounding framework exists alongside this, not in opposition to it, for situations where the commercially available drug doesn't meet a specific patient's needs: the standard dose doesn't work for someone who needs a different strength, the patient is allergic to an excipient in the commercial formulation, the drug isn't commercially available in the needed form, or — crucially — the drug is in shortage and the commercial supply is inadequate to meet demand.

The 503A framework governs individual patient-specific compounding by licensed pharmacies: a patient gets a prescription, a pharmacist compounds the specific medication for that patient. The 503B framework governs outsourcing facilities that can compound in larger volumes without patient-specific prescriptions, which is how the larger-scale compounding that supplies telehealth platforms typically works. Both frameworks require a legitimate clinical basis for the compounding, and both prohibit compounding of substances that are "essentially a copy" of a commercially available approved drug — unless the drug is on the FDA's drug shortage list.

The semaglutide situation between roughly 2022 and early 2025 became the highest-profile example of how this framework creates and then closes access windows. Semaglutide — Ozempic and Wegovy — was on the FDA's drug shortage list during that period because demand dramatically exceeded supply. That shortage designation made compounding of semaglutide legally permissible: pharmacies could compound it, and they did, in very large quantities. Telehealth platforms built substantial businesses around compounded semaglutide. Patients who couldn't access or afford branded Wegovy could access compounded versions at lower cost. When the FDA removed semaglutide from the shortage list in early 2025, the legal basis for compounding it as essentially a copy of the approved drug evaporated. Enforcement actions followed. The window opened and then closed, and the closing was not a surprise to anyone who had read the regulatory framework carefully.

The broader peptide compounding landscape has a similar underlying logic. Certain peptides have been available for compounding because they existed in a regulatory space that accommodated them: they weren't FDA-approved drugs, they had histories of clinical use, they appeared on lists of bulk drug substances that the FDA had evaluated and not prohibited. BPC-157 is one of the most discussed examples. In 2023 and 2024, the FDA issued guidance and ultimately categorized BPC-157 as a substance that may not be used in compounding under the 503A and 503B frameworks because it presents safety concerns and has not been shown to be safe and effective for clinical use. That categorization effectively removed BPC-157 from the legal compounding space for pharmacies operating within those frameworks, regardless of the demand from clinicians and patients and regardless of the ongoing research interest in the compound. The category exists in some other channels — the "research chemical" market, which is not a regulated clinical context — but compounding pharmacies bound by federal law cannot legally include it in preparations.

Similar evaluations have been conducted or are in progress for other compounded peptides. The FDA's Bulk Drug Substances list — which governs what can be used as a starting material in 503A and 503B compounding — is actively maintained and updated. Substances can be added and removed. The addition of a substance to the list doesn't make it FDA-approved; it makes it permissible for compounding. The removal of a substance from the list — or an affirmative determination that it cannot be used — closes the compounding window. For clinicians and patients who have built treatment protocols around specific compounded peptides, this is a consequential process to monitor, because the legal availability of specific compounds can change on regulatory timelines that don't necessarily align with clinical expectations.

The GLP-1 enforcement activity has been instructive about how the FDA moves when it wants to close a compounding window. The agency doesn't typically move immediately against every pharmacy or prescriber in a field; it issues guidance, announces determinations, gives notice periods, and then takes enforcement action against the most prominent or egregious actors. The pattern is gradual escalation rather than sudden prohibition, which gives time for adaptation but also creates a window in which continued compounding activity carries legal risk that grows over time. Clinicians and pharmacies operating in the compounded peptide space who have not closely followed the FDA's determination process for specific substances may find themselves on the wrong side of an enforcement action not because they weren't paying attention to the science, but because they weren't paying attention to the regulatory calendar.

The state regulatory layer adds complexity. State pharmacy boards regulate compounding pharmacies within their jurisdictions, and state medical boards regulate prescribing physicians. The FDA sets federal standards, but states can impose additional requirements, and in practice the stringency of state oversight of compounded peptide prescribing and dispensing varies considerably. Some states have been particularly active in regulating telehealth prescribing for compounded medications: requiring in-person evaluation before certain prescriptions, limiting out-of-state telehealth prescribing, and imposing specific documentation requirements for controlled substances and certain other compounds. Others have maintained lighter-touch oversight. The patchwork creates a situation where the same clinical practice can be permissible in one state and potentially problematic in another, and the telehealth model that has driven much of the compounded peptide market explicitly involves cross-state prescribing and dispensing.

The international dimension is worth understanding even for patients who aren't personally sourcing compounds from outside the United States. The existence of accessible international markets for peptides that aren't legally available in the U.S. creates a gray market that pulls demand away from compliant U.S. channels and into supply chains with no regulatory oversight. The research chemical designation — primarily used in some European regulatory frameworks to describe compounds sold for research purposes but not for human use — has become a mechanism through which compounds with no clinical approval status circulate in practice for human consumption. The compounds labeled this way are sometimes of uncertain quality, manufactured without pharmaceutical GMP standards, and sold without clinical guidance. This is a known risk that the regulatory conversation rarely addresses directly, but it's part of the actual landscape of how people access peptides that fall outside the compounding framework.

The likely regulatory trajectory for the next five years reflects the maturation of the peptide therapeutic space. As more peptide drugs achieve FDA approval — and the clinical pipeline is producing approvals in metabolic, oncology, cardiovascular, and neurology indications at an increasing rate — the compounding framework becomes a narrower and narrower space for any peptide that shares a therapeutic target with an approved drug. The "essentially a copy" prohibition means that a compounded peptide that functions similarly to an approved drug at a similar indication faces legal jeopardy even if the specific peptide sequence hasn't been approved itself. This interpretation is contested by some compounding advocates, but the FDA's enforcement posture in the GLP-1 space has resolved some of that ambiguity in the agency's favor.

For clinicians, the practical question is whether the compounds they are prescribing are available through compounding frameworks that are currently legal, whether the regulatory basis for that availability is stable or potentially subject to an FDA determination that could change it, and whether the clinical rationale for compounding — patient-specific need that can't be met by a commercially available approved alternative — is genuinely documentable. The telehealth model that has made compounded peptide prescribing very accessible has also made it easy to operate at a scale and in a mode that looks less like patient-specific compounding and more like pharmaceutical manufacturing of unapproved drugs — which is a different legal category entirely. Regulators have noticed this distinction.

For patients, the regulatory uncertainty translates to a practical recommendation: understand that the peptides you may currently be accessing through compounding pharmacies or telehealth platforms may not always be accessible in the same way or through the same channels. That's not a reason to panic or to make rushed decisions based on fear of losing access; it's a reason to have a clear conversation with your prescribing provider about the clinical rationale for whatever you're taking, about what alternatives exist or are likely to exist, and about how the compounds you're using are categorized under current FDA guidance. Providers who are operating at the edge of legal compounding frameworks without monitoring regulatory developments are not serving their patients well, even if the clinical intentions are sound.

What doesn't change regardless of how the compounding framework evolves is the underlying biology. The mechanisms of the peptides in question — their effects on specific receptors, their research profiles, the reasons clinicians have found them useful — don't disappear because a regulatory determination makes them harder to access. What changes is the channel through which those mechanisms can be accessed, the quality and oversight standards applied to the compounds, and the legal risk distribution across patients, clinicians, and pharmacies. A peptide that is banned from compounding pharmacy dispensing but remains available in research chemical channels hasn't become safer; it's become less regulated. That distinction matters.

The honest framing of regulatory uncertainty is this: the current landscape for compounded peptides reflects an interim state, not a stable equilibrium. The window that has made a wide range of compounded peptides accessible through legal clinical channels was created by the early-stage nature of the field, specific shortage conditions, and regulatory bandwidth constraints that haven't allowed comprehensive evaluation of every compound in the space. That window is closing gradually as the field matures, as drug approvals accumulate, and as the FDA works through its evaluation backlog. The appropriate response to that reality isn't fatalism or circumvention — it's staying informed, working with providers who are tracking the regulatory environment seriously, and not building clinical strategies around access patterns that may shift.